FORM 3

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

## INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF

OMB APPROVAL

OMB Number: 3235-0104

Estimated average burden hours per response: 0.5

## SECURITIES

or Section 30(h) of the Investment Company Act of 1940 3. Issuer Name and Ticker or Trading Symbol 2. Date of Event 1. Name and Address of Reporting Person\* Requiring Statement ABBOTT LABORATORIES [ ABT ] Murray Corlis D (Month/Day/Year) 02/01/2012 4. Relationship of Reporting Person(s) to Issuer 5. If Amendment, Date of Original Filed (Last) (Middle) (First) (Check all applicable) (Month/Day/Year) 100 ABBOTT PARK ROAD 10% Owner Officer (give title Other (specify 6. Individual or Joint/Group Filing (Check below) below) Applicable Line) (Street) Senior Vice President Form filed by One Reporting Person **ABBOTT** 60064-6092 II. Form filed by More than One **PARK** Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned 2. Amount of Securities 3. Ownership 1. Title of Security (Instr. 4) 4. Nature of Indirect Beneficial Ownership Form: Direct (D) Beneficially Owned (Instr. 4) or Indirect (I) (Instr. 5) Common shares without par value 32,383 D Common shares without par value 6,936 Profit Sharing Trust(1) Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and 3. Title and Amount of Securities 6. Nature of Indirect Expiration Date (Month/Day/Year) Underlying Derivative Security (Instr. 4) Conversion Ownership Beneficial Ownership or Exercise Form: (Instr. 5) Price of Direct (D) Amount Derivative or Indirect (I) (Instr. 5) Security Number Date Expiration of Exercisable Date Title **Shares** 02/15/2005 02/14/2012 Option (right to buy)(2) 1.890 53,625 D Common shares Option (right to buy)<sup>(2)</sup> 02/15/2005 02/14/2012 Common shares 481 53.625 D Option (right to buy)(3) 02/15/2017 Common shares 1,900 52.54 D 02/16/2009 Option (right to buy)(3) 02/16/2010 02/15/2017 Common shares 1,900 52.54 D Option (right to buy)(3) 02/15/2009 02/14/2018 1,934 55.56 D Common shares Option (right to buy)(3) 1,933 55.56 02/15/2010 02/14/2018 Common shares D Option (right to buy)(3) 02/15/2011 02/14/2018 Common shares 1,933 55.56 D 02/20/2010 02/19/2019 4,267 54.14 D Option (right to buy)(3) Common shares 54.14 Option (right to buy)(3) 02/20/2011 02/19/2019 4.267 D Common shares Option (right to buy)(3) 02/20/2012 02/19/2019 Common shares 4,266 54.14 D Option (right to buy)(4) 02/19/2011 02/18/2020 Common shares 3,234 54.5 D Option (right to buy)(4) 02/19/2012 02/18/2020 Common shares 3.233 54.5 D Option (right to buy)(4) 02/19/2013 02/18/2020 Common shares 3,233 54.5 D Option (right to buy)(4) 02/18/2012 02/17/2021 Common shares 3,534 46.6 D Option (right to buy)(4) 02/18/2013 02/17/2021 Common shares 3,533 46.6 D Option (right to buy)(4) 02/18/2014 02/17/2021 Common shares 3,533 46.6 D

## Explanation of Responses:

- 1. Balance in the Abbott Laboratories Stock Retirement Trust as of February 1, 2012.
- 2. Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3.
- 3. Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.
- 4. Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.

John A. Berry, by Power of Attorney for Corlis D. Murray

02/08/2012

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

The undersigned constitutes and appoints LAURA J. SCHUMACHER, JOHN A. BERRY, and STEVEN L. SCROGHAM, and each of them individually, as the undersigned's true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for the undersigned and in the undersigned's name, place and stead, to prepare and sign any and all Securities and Exchange Commission ("SEC") Notices of Proposed Sales of Securities pursuant to Rule 144 under the Securities Act of 1933 on Form 144, all SEC statements on Forms 3, 4 and 5 as required under Section 16(a) of the Securities Exchange Act of 1934, and any amendments to such forms, and to file the same with all exhibits thereto, and other documents in connection therewith, with the SEC, granting unto said attorney-in-fact and agent full power and authority to do and perform each act and thing requisite and necessary to be done under said Rule 144 and Section 16(a), as fully for all intents and purposes as the undersigned might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent may lawfully do or cause to be done by virtue hereof.

A copy of this power of attorney shall be filed with the SEC. The authorization set forth above shall continue in full force and effect until the undersigned is no longer required to file Forms 144, 3, 4, or 5 or if earlier, until the undersigned revokes such authorization by written instructions to the attorney-in-fact.

Date: February 1, 2012

/s/ Corlis D. Murray Signature of Reporting Person Corlis D. Murray, Name

Abbott Laboratories 100 Abbott Park Road Abbott Park, IL 60064-6400